| 摘要 |
The present invention relates to the use of one or more MHC class I molecules dextramers (Dextramers®) associated with peptides corresponding to Apoptotic Epitopes of human CD8+ T cells for the predictive prognosis of responsiveness or non-responsiveness to treatments and/or for monitoring the therapeutic effectiveness of treatments with biological medicaments that block and/or inhibit TNF, and/or biological medicaments that block and/or inhibit cytokines or cytokine receptors and/or biological medicaments against B cells and/or biological medicaments that inhibit T cell co-stimulation in patients affected by autoimmune diseases, together with methods and kits for said predictive prognosis. |
